248 related articles for article (PubMed ID: 28715437)
41. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer.
Ko E; Kim Y; Park SE; Cho EY; Han J; Shim YM; Park J; Kim DH
Lung Cancer; 2012 Aug; 77(2):401-6. PubMed ID: 22534667
[TBL] [Abstract][Full Text] [Related]
42. Serum microRNA-135a downregulation as a prognostic marker of non-small cell lung cancer.
Zhang YK; Sun B; Sui G
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27525941
[TBL] [Abstract][Full Text] [Related]
43. VEGF and IL-18 in induced sputum of lung cancer patients.
Rovina N; Hillas G; Dima E; Vlastos F; Loukides S; Veldekis D; Roussos C; Alhanatis M; Bakakos P
Cytokine; 2011 Jun; 54(3):277-81. PubMed ID: 21398142
[TBL] [Abstract][Full Text] [Related]
44. Interleukin 17A polymorphism elevates gene expression and is associated with increased risk of nonsmall cell lung cancer.
Cheng S; Shao Z; Liu X; Guo L; Zhang X; Na Q; Chen X; Ma Y; Zheng J; Song B; Liu J
DNA Cell Biol; 2015 Jan; 34(1):63-8. PubMed ID: 25289477
[TBL] [Abstract][Full Text] [Related]
45. Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer.
Chen B; Tan Z; Gao J; Wu W; Liu L; Jin W; Cao Y; Zhao S; Zhang W; Qiu Z; Liu D; Mo X; Li W
J Exp Clin Cancer Res; 2015 Oct; 34():126. PubMed ID: 26490682
[TBL] [Abstract][Full Text] [Related]
46. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
Ishikawa S; Nakagawa T; Miyahara R; Kawano Y; Takenaka K; Yanagihara K; Otake Y; Katakura H; Wada H; Tanaka F
Clin Cancer Res; 2005 Feb; 11(3):1198-202. PubMed ID: 15709189
[TBL] [Abstract][Full Text] [Related]
47. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
[TBL] [Abstract][Full Text] [Related]
48. [Correlations of S100A4 and MMP9 expressions to infiltration, metastasis and prognosis of non-small cell lung cancer].
Chen XL; Wang LC; Zhang WG; Chen XY; Sun ZM
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1254-8. PubMed ID: 18676277
[TBL] [Abstract][Full Text] [Related]
49. Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.
Ghasemkhani N; Shadvar S; Masoudi Y; Talaei AJ; Yahaghi E; Goudarzi PK; Shakiba E
Diagn Pathol; 2015 Sep; 10():164. PubMed ID: 26377406
[TBL] [Abstract][Full Text] [Related]
50. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.
Cheng TL; Chang MY; Huang SY; Sheu CC; Kao EL; Cheng YJ; Chong IW
Chest; 2005 Sep; 128(3):1453-60. PubMed ID: 16162743
[TBL] [Abstract][Full Text] [Related]
51. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
[TBL] [Abstract][Full Text] [Related]
52. Clinical relevance of galectin-1 expression in non-small cell lung cancer patients.
Carlini MJ; Roitman P; Nuñez M; Pallotta MG; Boggio G; Smith D; Salatino M; Joffé ED; Rabinovich GA; Puricelli LI
Lung Cancer; 2014 Apr; 84(1):73-8. PubMed ID: 24560493
[TBL] [Abstract][Full Text] [Related]
53. Aberrant expression of Per1, Per2 and Per3 and their prognostic relevance in non-small cell lung cancer.
Liu B; Xu K; Jiang Y; Li X
Int J Clin Exp Pathol; 2014; 7(11):7863-71. PubMed ID: 25550826
[TBL] [Abstract][Full Text] [Related]
54. HSPA2 is expressed in human tumors and correlates with clinical features in non-small cell lung carcinoma patients.
Scieglinska D; Gogler-Piglowska A; Butkiewicz D; Chekan M; Malusecka E; Harasim J; Habryka A; Krawczyk Z
Anticancer Res; 2014 Jun; 34(6):2833-40. PubMed ID: 24922646
[TBL] [Abstract][Full Text] [Related]
55. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
56. [Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC)].
Liu YQ; Guo RH; Liu LK; Gao W; Zhu CJ; Wei J; Shu YQ
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):426-30. PubMed ID: 21875482
[TBL] [Abstract][Full Text] [Related]
57. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
[TBL] [Abstract][Full Text] [Related]
58. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
59. Expression and clinical significance of aminopeptidase N/CD13 in non-small cell lung cancer.
Zhang Q; Wang J; Zhang H; Zhao D; Zhang Z; Zhang S
J Cancer Res Ther; 2015; 11(1):223-8. PubMed ID: 25879366
[TBL] [Abstract][Full Text] [Related]
60. RBX1 expression is an unfavorable prognostic factor in patients with non-small cell lung cancer.
Xing R; Chen KB; Xuan Y; Feng C; Xue M; Zeng YC
Surg Oncol; 2016 Sep; 25(3):147-51. PubMed ID: 27566015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
